A breath of fresh air
Transforming lives by treating diseases
caused by epithelial dysfunction.
EpiEndo Pharmaceuticals
We are a clinical-stage biopharmaceutical company with a unique approach to developing drugs for chronic inflammatory diseases, focusing on enhancing epithelial integrity.
About epithelial dysfunction and EP395
The Connection Between Epithelial Integrity Loss and Lung Inflammation
EpiEndo Pharmaceuticals is founded on the hypothesis that acute exacerbations of chronic airway diseases (CADs) are primarily triggered by insults to the epithelial barrier of the airways, leading to its breakdown. As a result, EpiEndo Pharmaceuticals aims to expand the therapeutic and diagnostic approaches for CADs beyond bronchoconstriction and inflammation.
Epithelial cells are a key part of the barrier that makes up human lung tissue and other organs. A breakdown of this barrier is implicated in several chronic inflammatory conditions, including COPD and other lung diseases. By enhancing this integrity, our lead compound, EP395, aims to reduce inflammation, slowing disease progression.
A Promising Solution for COPD Patients
COPD is the third largest cause of death globally, causing irreversible airflow obstruction. EP395, an oral barrier-enhancing and anti-inflammatory drug, which has the potential to be a unique and impactful treatment option for COPD patients.
4.8trn
is the global economic burden of COPD by 2030
3rd
COPD is leading cause of death globally
20bn+
COPD therapeutic market size by 2026
Developing First-in-Class Drugs to Address Chronic Respiratory Diseases
Our new class of oral drugs, known as BarriolidesTM, have the potential to be first-in-class therapies for respiratory diseases and beyond.
We have a unique approach to developing drugs for chronic inflammatory diseases, based on over 20 years of research into macrolides and their effects on the lung epithelium. The central focus of our pathophysiological models is on the integrity of the bronchial epithelial barrier, emphasising its breakdown, maladaptation, and dysfunction caused by persistent or overwhelming injury to the airway's mucosal lining.
This shift in perspective establishes a new theoretical basis for understanding, diagnosing, and treating CADs as epithelial diseases rooted in membrane pathology and barrier failure, rather than considering them solely as inflammatory diseases characterised by immune pathology and inappropriate or hyperactive inflammatory responses.
Our Team
Dedicated Experts
We are led by a passionate and highly experienced team with deep scientific knowledge and clinical and pharmaceutical industry expertise. Our team of dedicated professionals is committed to making a difference in the lives of respiratory disease patients.
Chief Executive Officer
Chief Financial Officer
Chief Medical Officer
Chief Operating Officer
Director of Research
Chairman of the Board
Board Member
Board Member
Board Member
Board Member
Board Member
SAB
SAB
SAB
SAB
SAB
SAB
SAB
SAB
SAB
News & Events
02 Nov 2023
REYKJAVIK, ICELAND – 2 November 2023 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutics addressing chronic airway diseases, has initiated a healthy volunteer drug-drug interaction (DDI) clinical trial for lead compound, EP395.
23 Oct 2023
REYKJAVIK, ICELAND – 23 October 2023 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutics addressing chronic airway diseases, has completed its proof of pharmacology study for lead asset EP395 in healthy volunteers.
23 Aug 2023
REYKJAVIK, ICELAND - 23 August 2023 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutic addressing chronic airway diseases, has contributed to a chapter in a key medical textbook, published this month.
16 Aug 2023
REYKJAVIK, ICELAND - 16 August 2023 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutic addressing chronic airway diseases, will have data presented in three abstracts at the European Respiratory Society (ERS) International Congress 2023 in Milan, Italy.
Sustainability
EpiEndo's Commitment to a Better Future
We are committed to sustainability and to minimizing our environmental impact and we are working towards formalizing our ESG policies. We measure ourselves against the United Nations Sustainable Development Goals and have implemented internal goals and policies that align with these goals.
Our key pillars
Ensure healthy lives and promote well-being for all at all ages
EpiEndo aims to improve the quality of life of people with chronic diseases caused by epithelial dysfunction.
Promote inclusive and sustainable economic growth, employment and decent work for all
EpiEndo is committed to having an inclusive work culture with a healthy balance between work and private life.
Build resilient infrastructure, promote sustainable industrialization and foster innovation
EpiEndo, through its collaborative way of working, will continue to innovate and expand the life-science industry in Iceland.
Ensure sustainable consumption and production patterns
Epiendo works towards responsible consumption and production internally and externally.
Our values
At EpiEndo, we are dedicated to conducting our business with integrity and upholding the highest ethical standards. Our code of conduct sets the standard for our employees, partners, and suppliers, and outlines our commitment to ethical behavior, compliance with laws and regulations, and respect for the rights and dignity of all individuals. Our code of conduct reflects our values and our commitment to conducting business with the highest level of professionalism and ethical standards.
NEWS & EVENTS
